fashion -WSS

fashion

author：knowledge 2025-09-30 23:07:35 - browse：2981

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Readout Newsletter: The latest on Novavax, Merck, Bluebird

WSS

FDA panel gives mixed vote on blood pressure devices

How generative AI ratchets up security threats for health systems

How to make Best Hospitals ratings actually useful for patients

Why more medical students aren't specializing in primary care

Zyn nicotine pouches become unlikely player in latest culture war

How generative AI ratchets up security threats for health systems

explore

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

How one medical school became remarkably diverse

Humana’s losses in Medicare Advantage tank its stock

Medical leaders decry Supreme Court decision on affirmative action

How to make Best Hospitals ratings actually useful for patients

Malaria cases in Florida and Texas: Here’s what you need to know

Humana’s losses in Medicare Advantage tank its stock

State Dept. review finds Biden bears some blame for Afghanistan failures

Radiation, mainstay of cancer treatment, begins a fade

BioMarin wins approval for gene therapy to treat hemophilia A

Appeals court upholds limits to abortion pill

knowledge

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Health Care Service Corp to buy Cigna Medicare Advantage plans

Venture capital firm's plans to take over Akron hospital face hurdles

Complete sequence of Y chromosome published for first time

How Long Island became the ‘eugenics capital of the world’

entertainment

knowledge

entertainment

entertainment